ArticleInternational journal of oncology2019
[Corrigendum] miR‑122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box O3.
Article in International journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Review of Recent Research on the Role of MicroRNAs in Renal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2021Review
- The Ambivalent Role of miRNAs in Carcinogenesis: Involvement in Renal Cell Carcinoma and Their Clinical Applications.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma.Cancers · 2019Review
Corrections and comments
- Erratum for
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the publication of this paper, the authors have realized that two out of the three of the authors' address affiliations were not presented correctly. Essentially, the information provided in the first and third address affiliations was confused (and there is no third address affiliation applicable to this study), and the Chinese People's Liberation Army Hospital for the first affilation was presented incorrectly with a Weifang address. In spite of these errors in the affiliations, note that the corresponding author's address featured in the Correspondence box was presented correctly in the paper. Therefore, the authors' affiliations, and the affliation addresses, should have appeared as follows: WENYUAN NIE1*, DONG NI2*, XIN MA1, YU ZHANG1, YU GAO1, CHENG PENG1 and XU ZHANG1. 1Department of Urology, State Key Laboratory of Kidney Diseases, Chinese People's Liberation Army General Hospital, PLA Medical School, Beijing 100853; 2Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China. *Contributed equally. The authors confirm that there are no further errors in the study, and all the authors agree to this correction. The authors regret this error in the affiliations, and apologize for any inconvenience caused. [the original article was published in International Journal of Oncology 54: 559‑571, 2019; DOI: 10.3892/ijo.2018.4636].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.